SCHEMBL25232452

SCHEMBL25232452

CC(C)(C)[S@@+]([O-])N=Cc1ccccc1Br

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.40
KMT2A Q03164 5/20 0.39
ATM Q13315 1/20 0.39
MAPT P10636 7/20 0.37
GAA P10253 2/20 0.37
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
RAB9A P51151 4/20 0.34
NPC1 O15118 3/20 0.34
HTT P42858 2/20 0.34
TP53 P04637 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HSD11B1 P28845 3/20 0.33
LMNA P02545 1/20 0.33
IKBKB O14920 1/20 0.33
DYRK2 Q92630 1/20 0.33
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23579546 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL30311358 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL31267503 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL30268879 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL23579547 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL25232450 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL25472036 1.00 GPR3 (0.40) GPR3KMT2AATMMAPTGAA
SCHEMBL29905100 0.84 LMNA (0.35) GPR3MAPTGAASMN1; SMN2LMNA
SCHEMBL4933768 0.81 GPR3 (0.41) GPR3KMT2AMAPTGAAMEN1
SCHEMBL4933775 0.81 GPR3 (0.41) GPR3KMT2AMAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 GPR3 4324/4885KMT2A 2209/4885ATM 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.